Filing Details

Accession Number:
0001209191-13-024162
Form Type:
4
Zero Holdings:
No
Publication Time:
2013-05-06 16:29:43
Reporting Period:
2013-05-02
Filing Date:
2013-05-06
Accepted Time:
2013-05-06 16:29:43
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
875320 Vertex Pharmaceuticals Inc / Ma VRTX Pharmaceutical Preparations (2834) 043039129
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1446372 M Paul Silva C/O Vertex Pharmaceuticals Incorporated
130 Waverly St.
Cambridge MA 02139
Svp & Corp Controller No Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2013-05-02 1,125 $37.86 12,875 No 4 M Direct
Common Stock Disposition 2013-05-02 700 $77.17 12,175 No 4 S Direct
Common Stock Disposition 2013-05-02 425 $77.59 11,750 No 4 S Direct
Common Stock Acquisiton 2013-05-03 937 $38.80 12,687 No 4 M Direct
Common Stock Disposition 2013-05-03 637 $75.76 12,050 No 4 S Direct
Common Stock Disposition 2013-05-03 200 $76.66 11,850 No 4 S Direct
Common Stock Disposition 2013-05-03 100 $78.12 11,750 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 M Direct
No 4 S Direct
No 4 S Direct
No 4 M Direct
No 4 S Direct
No 4 S Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Stock Option (right to buy) Disposition 2013-05-02 1,125 $0.00 1,125 $37.86
Common Stock Stock Option (right to buy) Disposition 2013-05-03 937 $0.00 937 $38.80
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
12,375 2022-02-01 No 4 M Direct
6,563 2021-02-02 No 4 M Direct
Reported Non-Derivative Holdings
Sec. Name Remaning Holdings Nature of Ownership Explanation
Common Stock 169 Indirect 401(k)
Footnotes
  1. Transaction made pursuant to Mr. Silva's company approved trading plan under Rule 10b5-1.
  2. Open market sales reported on this line occurred at a weighted average price of $77.17 (range $76.48 to $77.41).
  3. Mr. Silva undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price.
  4. Open market sales reported on this line occurred at a weighted average price of $77.59 (range $77.49 to $77.72).
  5. Open market sales reported on this line occurred at a weighted average price of $75.76 (range $75.42 to $76.21).
  6. Open market sales reported on this line occurred at a weighted average price of $76.66 (range $76.47 to $76.85).
  7. The option vests in 16 quarterly installments beginning on 02/02/2012.
  8. The option vests in 16 quarterly installments beginning on 02/03/2011.